急性心肌梗塞(AMI)病人於住院期間給藥比率-阿斯匹靈(Aspirin)(疾病別指標)

健保署為加強心肌梗塞病患醫療品質，擇定具實證醫學指標項目作公開，作為相關疾病就醫時或健康照護品質的參考；公開項目依治療期間及品質面向共分三大類，包括住院期間過程面評估、出院持續藥物治療評估及結果面評估。包含急性心肌梗塞(AMI)病人於住院期間執行血脂LDL檢查比率、急性心肌梗塞(AMI)病人於住院期間、出院後三個月、六個月、九個月內給藥比率、病人出院後三日以內因同一主診斷或相關病情之急診返診比率、病人出院後十四日以內因同一主診斷或相關病情之非計畫性再住院比率等。

To enhance the quality of medical care for patients with myocardial infarction, the National Health Insurance Administration has selected evidence-based medical indicator items for public disclosure, which serve as a reference for medical consultation for related diseases and health care quality assessment. The disclosed items are categorized into three major groups based on treatment phases and quality dimensions: in-hospital process assessment, post-discharge continuous medication treatment assessment, and outcome assessment. The covered indicators include: the proportion of acute myocardial infarction (AMI) patients who underwent serum lipid LDL testing during hospitalization; the proportion of AMI patients who received prescribed medications during hospitalization and within 3, 6, and 9 months after discharge; the proportion of patients who returned to the emergency department within 3 days after discharge due to the same primary diagnosis or related conditions; and the proportion of unplanned readmissions within 14 days after discharge due to the same primary diagnosis or related conditions, among others.

搜集汇总

背景与挑战

背景概述

该数据集由健保署公开，旨在通过实证医学指标提升急性心肌梗塞(AMI)患者的医疗品质，重点关注住院期间阿斯匹灵(Aspirin)的给药比率。它属于疾病别指标，涵盖住院过程评估、出院后药物持续治疗及结果评估等多个方面，包括血脂检查、不同时间点给药比率以及再住院和返诊比率等相关指标。